Navigation Links
2-drug combination appears safe and active in metastatic kidney cancer
Date:5/31/2009

ORLANDO (May 31, 2009)Fox Chase Cancer Center investigators report that a two-drug blockade of mTOR signaling appears safe in metastatic kidney cancer in a phase I trial. Early data suggests that a combination of temsirolimus and bryostatin may be active in patients with rare forms of renal cell cancer, which are less likely to respond to other targeted therapies.

Elizabeth Plimack, M.D., M.S., a medical oncologist and attending physician at Fox Chase will report the trial results on Sunday, May 31 at the annual meeting of the American Society of Clinical Oncology.

"We have certainly seen sustained responses with this combination which are encouraging," Plimack says.

One of the patients with an extended response has papillary renal cell cancer, which is a rare form of the disease that does not respond well to standard therapies. "Patients with non-clear cell renal cell cancer, including papillary renal cancer, don't respond as well to tyrosine kinase inhibitors, such as sunitinib and sorafenib, as patients with clear cell renal cell. So there is an unmet need for therapy for these patients. We've seen that this combination may be active to some degree for them."

mTOR signaling promotes tumor cell proliferation and blood vessel development. Temsirolimus (Torisel), blocks signaling through one portion of the mTOR signaling complex, called TORC1, and slows tumor progression in patients with advanced kidney cancer. However, a second portion of the complex, called TORC2, is unaffected by temsirolimus and continues to promote cell proliferation. Therefore, Plimack and colleagues suspect that blocking TORC2 signaling activity could improve patient outcomes. Bryostatin blocks a downstream effector of TORC2, called protein kinase C.

Plimack and colleagues designed the phase I trial to test the safety of the bryostatin-temsirolimus combination. Twenty-five patients enrolled in the trial, including 20 patients with renal cell
'/>"/>

Contact: Diana Quattrone
Diana.Quattrone@fccc.edu
215-728-7784
Fox Chase Cancer Center
Source:Eurekalert

Page: 1 2

Related medicine news :

1. 2-drug blood pressure therapy lowers cardiovascular risk
2. New treatment combination proves safe for head and neck cancer patients
3. Study shows drug combination improves outcome for advanced non-small cell lung cancer
4. Chemotherapy combination outcomes differ for aged, younger colon cancer patients
5. Phase 3 Trial Initiated to Evaluate Combination Therapy of Nexavar(R) and Tarceva(R) in Patients with Liver Cancer
6. Transplant Surgery and Identity: A Discussion Among Pioneers with Unusual Combinations of Interests, Skills and Talents
7. Mayo Clinic Researchers Say Triple Drug Combination is Promising Option to Treat Metastatic HER2+ Breast Cancer
8. HealthWarehouse.com, Inc. Announces Completion of Business Combination With Clacendix, Inc.
9. Triple drug combination is promising option to treat metastatic HER2+ breast cancer
10. Plavix, Heartburn Drugs May Be Risky Combination
11. Fixed Dosed Combination Agents and Novel Antihypertensives Are Expected to Face Tougher Formulary Restrictions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2015)... ... August 29, 2015 , ... ProDrop Particles includes over 40 particle ... 15 seconds of unique footage that users can shrink and stretch in the Final ... more. Users can customize color, brightness, scale, speed, range, and flare attributes with intuitive ...
(Date:8/29/2015)... (PRWEB) , ... August 29, 2015 , ... ... the company to freely market and sell Arterosil and Arterosil HP, and that ... Sciences, LLC (DHS) sued Vascular Health Sciences, LLC (VHS) in the United States ...
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... ... No Malaria Day at the Zoo to celebrate children helping children, a thank ... their congregations throughout West Ohio have contributed to the United Methodist initiative to ...
(Date:8/28/2015)... ... , ... For Dallas, the time is nearing for the annual Heart Walk, ... , The American Heart Association hosts their well-known Heart Walk to raise money in ... difference can be made. Walkers can participate in the cause and someone can also ...
(Date:8/28/2015)... ... , ... On May 30th, 2015, Best Drug Rehabilitation, a results-based substance abuse ... Mission” benefit concert in Mendon, IL. Held in the Show Barn at the Adams ... education programs in the underfunded local school districts of Mendon at neighboring Quincy, IL. ...
Breaking Medicine News(10 mins):Health News:FCPX Effects Developer, Pixel Film Studios, Releases ProDrop Particles. 2Health News:Saturday’s United Methodist Event at Columbus Zoo Celebrates Imagine No Malaria 2Health News:Saturday’s United Methodist Event at Columbus Zoo Celebrates Imagine No Malaria 3Health News:North Central Surgical Center’s Subsidiary Participates in Walk 2Health News:New Video Released on "Music With A Mission" Benefit Concert Headlining Artist Cadillac Three & Best Drug Rehabilitation 2
... with profound hearing disabilities and President A.P.J.Abdul Kalam today ... to intensify their drive to reduce the number of ... the 3rd Cochlear Implant Group of India Conference in ... with severe hearing disability, 0.9 million people with moderate ...
... has been found to have less side effects and ... the allergen is given as a vaccine in order ... antibodies which are already present helps to counteract the ... injections against allergy diseases such as hay fever, cat ...
... leader Colgate-Palmolive Company has entered into an alliance with ... designed to fight against pre-cancerous //conditions in the oral ... this end Colgate purchased $20 million of Introgen shares ... by Introgen. Introgen has a wide range of molecular ...
... November issue of the Journal of the National Cancer Institute, ... treatment, and patients treated with the higher chemotherapy dose had ... testicular cancer is the most common cancer among 20-40 year ... age at which they are starting a family, and the ...
... that rheumatoid arthritis patients respond differently to the same ... new study now explains that it is due to ... following experiments conducted on animal models of mouse that ... such complex behaviors could enable physicians make an individualized ...
... FDA approved long-term treatment regime for patients with treatment ... now being offered to patients at NewYork-Presbyterian Hospital/Columbia University ... first treatment specifically approved for TRD in patients over ... been unsuccessful atleast in four or more of the ...
Cached Medicine News:Health News:Kalam Appeals to Eradicate Hearing Disability 2Health News:Oral Edible vaccine for Allergy Vaccines 2Health News:Decline in Paternity Rates Following Treatment for Testicular Cancer 2Health News:Study Offers Insights Into Treatment Of Rheumatoid Arthritis 2Health News:FDA Approved Nerve-Stimulation Therapy Now Available In New York 2
(Date:8/28/2015)... 2015  CytomX Therapeutics, Inc., a biopharmaceutical company developing ... the filing of a registration statement on Form S-1 ... to a proposed initial public offering of its common ... the price range for the offering have not yet ... under the symbol "CTMX" on the NASDAQ Global Market. ...
(Date:8/28/2015)... DUBLIN , Aug. 28, 2015 ... ) has announced the addition of the ... report to their offering. Originally discovered ... as Yoshitomi Pharmaceutical Industries, Ltd) as an inflammatory ... by Senju Pharmaceutical Co., Ltd under the trade ...
(Date:8/28/2015)... DUBLIN , Aug. 28, 2015 ... ) has announced the addition of the ... Capacity and Production" report to their offering. ... Survey of Biopharmaceutical Manufacturing Capacity and Production is ... contract manufacturing organizations, current and projected future capacity ...
Breaking Medicine Technology:CytomX Files Registration Statement for Proposed Initial Public Offering 2Investigation Report on China's Pranoprofen Market, 2010-2019 212th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production 2
... N.C., June 20, 2011 Pharmaceutical Institute, the ... pharmaceutical and biotech industry and a subsidiary of ... updates to its Therapeutic Area Essentials™ ... disease state training for pharmaceutical and biotech R&D ...
... dreamed of becoming a pilot for as long as he can ... child opting to play with toy planes instead of cars, and ... a family trip to Disney World.  At 8-years old Baniecki scribbled ... airline pilot and placed it into a time capsule.  Ten years ...
Cached Medicine Technology:Therapeutic Area Essentials "Class of 2011" Brings Current Disease State Training to Pharma 2Pilot's Dream Comes True Thanks to New Robotic Surgery 2Pilot's Dream Comes True Thanks to New Robotic Surgery 3Pilot's Dream Comes True Thanks to New Robotic Surgery 4
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: